November 14, 2019
Due to last-minute scheduling conflicts, we must postpone Friday’s (Nov 15) webinar—PK, PD and F/TAF: What does an advocate need to know about the pharmacology of safety and efficacy and today’s PrEP drugs. We apologize for the inconvenience but stay tuned for details on its rescheduling!
And, in case you missed it, download and view the rest of the webinar series via the links below:
Trial Design Takes a Step in the Post PrEP Era: What will Gilead’s study of F/TAF among cisgender women tell us about next gen PrEP and next-gen trial design [Nov 13]
Gilead is designing a novel trial, planned to begin in Africa in 2020, to gather missing data about the safety and efficacy of F/TAF among cisgender women. What are the implications of this trial? The FDA’s Jeff Murray presented how an innovative design will enable a relatively smaller trial, and the questions it raises.
Recording and Slides: YouTube / Jeff Murray’s Slides
It’s Complicated—Implementation questions regarding price, programming and policies for Descovy as PrEP [Nov 11]
An array of experts helped us sift through the questions on pricing, policy and programming related to Descovy, none of which have easy answers, all of which have significant implications for PrEP implementation in the United States.
Recording and Slides: YouTube / David Hardy and Craig Hendrix’s Slides / Amy Killelea and Tim Horn’s Slides
Advocates’ Debrief on the Science of Daily F/TAF vs. TDF/FTC as PrEP [Oct 7]
This webinar was the first the series, responding to advocates’ desire to better understand the research to date on F/TAF as PrEP, especially as it relates to its safety profile [compared to TDF/FTC] and the lack of robust data in cisgender women.
Recording and Slides: YouTube / Andrew Hill’s slides / Monica Gandhi’s slides
For additional background visit our F/TAF page on our website at www.avac.org/ftaf.